Debiovision integrates into the Debio Group
Quebec-based company was formerly known as H3 Pharma
Debiovision, formerly known as H3 Pharma, a Quebec-based company focusing on the development of specialty pharmaceuticals, has been integrated into the Debio Group following the purchase of all the outstanding shares of H3 Pharma earlier this year.
A fully owned affiliate of Debiopharm, the independent drug development company specialising in oncology, endo-crinology, CNS and niche products, Debiovision com-plements the existing companies in the Debio Group: Debiopharm, Debioinnovation and Debio R.P. in Switzerland and Debioclinic in France.
Founded in 2001, Debiovision will focus on the development and worldwide registration of speciality pharmaceuticals. In addition, it will provide support to the Group on development and regulatory activities in North America. In particular, Debiovision will enable the Group to optimise its Phase I clinical trial activities in Canada.
Debiovision has three products in its pipeline including Sanvar, which was submitted to the US FDA and received an approvable letter in December 2004, and SC-1 and PAM-1, two fully human monoclonal antibodies.
Debiovision is actively negotiating out-licensing agreements for Sanvar with US, Asian and Latin American partners and is beginning out-licensing discussions in Europe in conjunction with the preparation of the European filing. Sanvar is for the treatment of acute esophageal variceal bleeding (EVB) secondary to portal hypertension. It is also undertaking out-licensing activities for SC-1 for stomach cancer and PAM-1 for adenocarcinomas, including pancreatic cancer.
'Having Debiovision is an important asset for Debio's drug development activities and a presence in North America will enhance our worldwide capability,' said Rolland-Yves Mauvernay, president and ceo of Debiopharm.
